Mortality trends in middle aged and older women in the Netherlands: beneficial effect of menopausal hormone therapy

Maturitas ◽  
2015 ◽  
Vol 81 (1) ◽  
pp. 127
Author(s):  
Ingrid Pinas ◽  
Niels Erich ◽  
Dorly Deeg
Keyword(s):  
The Netherlands ◽  
Beneficial Effect ◽  
Hormone Therapy ◽  
Older Women ◽  
Menopausal Hormone Therapy ◽  
Middle Aged ◽  
Mortality Trends

Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women

Menopause ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ji-Eun Kim ◽  
Jaesung Choi ◽  
JooYong Park ◽  
Aesun Shin ◽  
Nam-Kyong Choi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Diseases ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Middle Aged

scholarly journals Patterns of menopausal hormone therapy use and hyperkyphosis in older women

2018 ◽  
Vol 25 (7) ◽  
pp. 738-743 ◽  
Author(s):  
Gina N. Woods ◽  
Mei-Hua Huang ◽  
Peggy M. Cawthon ◽  
Corinne McDaniels-Davidson ◽  
Howard A. Fink ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Older Women ◽  
Menopausal Hormone Therapy

scholarly journals Associations of Hearing Loss and Menopausal Hormone Therapy With Change in Global Cognition and Incident Cognitive Impairment Among Postmenopausal Women

2019 ◽  
Vol 75 (3) ◽  
pp. 537-544 ◽  
Author(s):  
Nicole M Armstrong ◽  
Mark A Espeland ◽  
Jiu-Chiuan Chen ◽  
Kamal Masaki ◽  
Jean Wactawski-Wende ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Hearing Loss ◽  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Older Women ◽  
Normal Hearing ◽  
Menopausal Hormone Therapy ◽  
Global Cognition

Abstract Background Hearing loss (HL) and menopausal hormone therapy (conjugated equine estrogens [CEE] and/or medroxyprogesterone acetate [MPA]) are separately associated with cognitive decline and increased risk of incident cognitive impairment. Joint effects of HL and HT could be associated with additive or synergistic decline in global cognition and risk of incident cognitive impairment among postmenopausal women. Methods Using the Women’s Health Initiative (WHI) Memory Study, 7,220 postmenopausal women with measures of HL, global cognition (Modified Mini-Mental State Examination score), and cognitive impairment (centrally adjudicated diagnoses of mild cognitive impairment and dementia) from 1996 to 2009. Multivariable linear mixed-effects models were used to analyze rate of change in global cognition. Accelerated failure time models were used to evaluate time to incident cognitive impairment, stratified by HT. Results Within the CEE-Alone trial, observed adverse effects of CEE-Alone on change in global cognition did not differ by HL, and estimated joint effects of HL and CEE-Alone were not associated with incident cognitive impairment. Within the CEE+MPA trial, while HL did not independently accelerate time to cognitive impairment, the adverse effect of CEE+MPA on global cognition was heightened in older women with HL. Older women on CEE+MPA either with HL (time ratio [TR] = 0.82, 95% confidence interval [CI]: 0.71, 0.94) or with normal hearing (TR = 0.86, 95% CI: 0.76, 0.97) had faster time to cognitive impairment than those with normal hearing and placebo. Conclusions HL may accentuate the adverse effect of CEE+MPA, not CEE-Alone, on global cognitive decline, not incident cognitive impairment, among postmenopausal women on HT.

scholarly journals Menopausal Hormone Therapy and Suicide in a National Sample of Midlife and Older Women Veterans

Medical Care ◽  
2021 ◽  
Vol 59 ◽  
pp. S70-S76 ◽  
Author(s):  
Carolyn J. Gibson ◽  
Yixia Li ◽  
Guneet K. Jasuja ◽  
Kyle J. Self ◽  
Karen H. Seal ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Older Women ◽  
Women Veterans ◽  
National Sample ◽  
Menopausal Hormone Therapy

Menopausal hormone therapy and uterine cancer: the acceptability of the tandem

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (6) ◽  
pp. 42-47
Author(s):  
O V Yakushevskaya ◽  
S V Yureneva ◽  
A E Protasova ◽  
G N Khabas ◽  
M R Dumanovskaya
Keyword(s):  
Hormone Therapy ◽  
Uterine Cancer ◽  
Menopausal Hormone Therapy ◽  
Medical Rehabilitation ◽  
Cytostatic Treatment ◽  
Systematic Analysis ◽  
Strict Adherence ◽  
Patient Profile ◽  
The Past

The aim of the work is to conduct a systematic analysis of the available research results on the possibility of using menopausal hormone therapy (MHT) in patients who successfully completed the treatment of endometrial cancer (EC). Materials and methods. The review includes data from foreign articles published in PubMed and Medline, and domestic works published on elibrary.ru over the past 40 years. Results. The results obtained allow us to consider MHT as an independent method of medical rehabilitation for women who have undergone EC. A clear patient profile should be established, allowing the use of this method, with strict adherence to health monitoring. Conclusion Patients who have successfully completed the treatment of EC require the creation of special rehabilitation conditions in the interests of maintaining health and quality of life and should be under the close attention of the doctor. Argumented approaches to the appointment of MHT in such patients will avoid complications associated with estrogen deficiency after surgery, radiation with or without systemic (cytostatic) treatment methods.

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document